

1 Elizabeth A. Fegan
2 FEGAN SCOTT LLC
3 150 S. Wacker Dr., 24th Fl.
4 Chicago, IL 60606
5 Ph: 312.741.1019
6 Fax: 312.264.0100
7 beth@feganscott.com

8 Additional Counsel for
9 Plaintiff Aaron Sheller on Signature Page

10 **UNITED STATES DISTRICT COURT**
11 **NORTHERN DISTRICT OF CALIFORNIA**

12 IN RE: ROUNDUP PRODUCTS
13 LIABILITY LITIGATION

MDL No. 2741
Case No. 16-md-02741-VC

14 This document relates to:

15 *Sheller v. Bayer AG, et al.*, Case No. 3:19-cv-
16 07972

17 *Ramirez, et al. v. Monsanto Co.*, Case No.
18 3:19-cv-02224

19 **PLAINTIFF AARON SHELLER'S**
20 **CORRECTED SECOND RENEWED**
21 **MOTION TO APPOINT FEGAN**
22 **SCOTT LLC AS INTERIM CLASS**
23 **COUNSEL FOR THE MEDICAL**
24 **MONITORING CLASS**

Hearing Date: September 24, 2020

Time: 10:00 a.m.

1 **TO THE COURT, ALL PARTIES, AND THEIR ATTORNEYS OF RECORD:**

2 **PLEASE TAKE NOTICE THAT** beginning on September 24, 2020 at 10:00 a.m., in
3 Courtroom 4 of the United States District Court, Northern District of California, located at 450
4 Golden Gate Avenue, San Francisco, CA 94102, or as ordered by the Court, Plaintiffs Aaron
5 Sheller and Kabe Cane (“Movants”) will present Mr. Sheller’s Second Renewed Motion to
6 Appoint Fegan Scott LLC as Interim Class Counsel for the Medical Monitoring Class.

7 Movants seek appointment of Fegan Scott LLC as Interim Class Counsel for the Medical
8 Monitoring Class. Movants’ Motion is brought pursuant to Fed. R. Civ. P. 23(g) and is based on
9 this Notice, the following memorandum of points and authorities, the exhibits appended thereto,
10 and any additional argument or evidence this Court may consider.

11
12 Dated: August 24, 2020

/s/ Elizabeth A. Fegan
Elizabeth A. Fegan
FEGAN SCOTT LLC
150 S. Wacker Dr., 24th Floor
Chicago, IL 60606
T: 312-741-1019
F: 312.264.0100
beth@feganscott.com

*Counsel for Movants and
Proposed Interim Lead
Counsel for the Medical
Monitoring Class*

TABLE OF CONTENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

- I. INTRODUCTION 1
- II. RELEVANT FACTUAL AND PROCEDURAL HISTORY 5
 - A. Summary of Factual Allegations against Defendants 5
 - B. The Litigations 5
 - C. The Withdrawn Settlement and Continuing Settlement Negotiations 7
 - 1. The proposed settlement terms disproportionately prejudiced the Medical Monitoring Class. 7
 - 2. The terms of the Settlement reflected immutable conflicts of interest which are important to understand the backdrop against which settlement negotiations continue. 8
 - D. Meet and Confers 9
- III. LEGAL STANDARD 9
- IV. ARGUMENT 10
 - A. Appointment of Interim Class Counsel is necessary to protect the interests of the Medical Monitoring Class. 10
 - B. Settling Counsel’s belated, informal designation of subclass counsel fails to protect the class’s interests. 12
 - C. Fegan Scott should be appointed interim class counsel. 14
- V. CONCLUSION 15

1 **TABLE OF AUTHORITIES**

2 **Cases**

3 *Ortiz v. Fibreboard Corp.*,
 4 527 U.S. 815 (1999) 4, 11, 12, 13

5 *Amchem Prods. v. Windsor*,
 6 521 U.S. 591 (1997) 4

7 *Hanlon v. Chrysler Corp.*,
 8 150 F.3d 1011 (9th Cir. 1998) 10, 11

9 *In re Navistar Maxxforce Engines Mktg., Sales Practices & Prods. Liab. Litig.*,
 10 No. 2590, 2015 U.S. Dist. LEXIS 34662 (N.D. Ill. Mar. 5, 2015) 10

11 *Literary Works in Elec. Databases Copyright Litig. v. Thomson Corp.*,
 12 654 F.3d 242 (2d Cir. 2011) 11, 13

13 *Simpkins v. Wells Fargo Bank, N.A.*,
 14 2013 WL 12051028 (S.D. Ill. June 28, 2013) 10

15 *Smith v. Sprint Commc’ns Co., L.P.*,
 16 387 F.3d 612 (7th Cir. 2004) 12

17 *Walker v. Discover Fin. Servs.*,
 18 No. 10-cv-6994, 2011 U.S. Dist. LEXIS 58803 (N.D. Ill. May 26, 2011) 10

19 **Rules**

20 Fed. R. Civ. P. 23 2, 4, 9, 10

21

22

23

24

25

26

27

28

1 **I. INTRODUCTION**

2 It is a fundamental principle in class actions and mass tort cases that “[f]uture claimants
3 must be separated from current claimants and represented by named plaintiffs and subclass counsel
4 whose loyalties run exclusively to them.” *See* Declaration of Professor Charles Silver on Adequacy
5 of Representation (“Silver Decl.”), at 6, attached as Ex. A. Professor Silver, the Roy W. and
6 Eugenia C. McDonald Endowed Chair in Civil Procedure at the University of Texas School of
7 Law and respected expert in the fields of, *inter alia*, professional responsibility and class actions,
8 explains:

9 The importance of ‘clarif[ying] responsibility for protecting the
10 interests of the [sub]class during precertification activities, such as .
11 . . negotiating settlement’ is obvious and cannot be exaggerated. All
12 settlement negotiations fix the amounts that claimants will receive.
13 When groups of plaintiffs with divergent interests compete for
14 shares of the amount a defendant is willing to contribute to a global
15 resolution, groups that are not represented by loyal advocates bent
16 on maximizing their recoveries must expect to be shortchanged.

17 Silver Decl. at 10-11. *See also id.*, Ex. 1 to Silver Declaration (Resume of Professor Charles
18 Silver). Despite this and despite Movants’ multiple meet and confers over the last 60 days, counsel
19 who have immutable conflicts of interest are currently negotiating a global settlement with
20 Defendants on behalf of both current and future claimants.

21 It is undisputed that the only plaintiff who was first to pursue, and has exclusively pursued,
22 medical monitoring for a class of persons who have been exposed to Roundup but who have not
23 yet manifested disease is Aaron Sheller and his counsel at Fegan Scott LLC, who filed their
24 original medical monitoring class action complaint in September 2019. Sheller has twice moved
25 to appoint Fegan Scott LLC as interim lead counsel for a subclass of Roundup users who seek
26 medical monitoring for the increased risk they face of developing non-Hodgkin’s lymphoma
27 (“NHL”) as result of Roundup exposure (the “Medical Monitoring Class”).¹ *See* ECF No. 9771.
28 *See also Sheller v. Bayer AG et al.*, No. 1:19-cv-4063 (S.D. Ind.) (ECF No. 19) (motion was

¹ Joining Mr. Sheller in this renewed motion is putative class member Kabe Cain (collectively,
“Movants”), who was a member of the Settlement Class in the Motion for Preliminary Approval
of Class Settlement, ECF No. 11042 (“Preliminary Approval Motion”).

1 pending when transferred to this MDL). Fegan Scott LLC has never represented any persons who
 2 have been diagnosed with NHL and thus the firm’s interests run exclusively to the Medical
 3 Monitoring Class. Nonetheless, Defendants continue to negotiate to settle the interests of the
 4 Medical Monitoring Class with attorneys who purport to simultaneously represent both current
 5 and future claimants, *rendering any negotiated settlement doomed* – regardless of the amount or
 6 structure – because of the inherent conflicts of interest. *See generally* Silver Decl.; *see also*
 7 *generally* Declaration of Mary Robinson, Esq. (legal expert in ethics and professional
 8 responsibility) (“Robinson Decl.”), attached as Ex. B.

9 At the time this Court decided Sheller’s first renewed motion, the Court recognized that
 10 the interests of the Medical Monitoring Class may diverge from those who have already been
 11 diagnosed with cancer (the “Personal Injury Plaintiffs”). ECF No. 10587 (Apr. 27, 2020 Pretrial
 12 Order No. 211). The Court nevertheless denied Mr. Sheller’s motion without prejudice, finding
 13 that a conflict was not yet apparent. *Id.* At the time, the Court noted, “the motion present[ed] no
 14 reason to believe that negotiations between Monsanto and the currently sick will impact any future
 15 negotiations between Monsanto and the exposure-only medical-monitoring class.” *Id.* at 2.

16 That statement is no longer true. Since the Court’s decision, certain plaintiffs’ counsel
 17 (“Settling Counsel”)² filed a motion to settle the claims of both the exposure-only Medical
 18 Monitoring Class and a class of Personal Injury Plaintiffs (the “Personal Injury Class”). *See*
 19 *generally* Preliminary Approval Motion (ECF No. 11042). That now-withdrawn motion and
 20 proposed settlement raised “concerns” that made the Court “skeptical of the propriety and fairness
 21 of the proposed settlement.” ECF No. 11182 (July 6, 2020 Pretrial Order No. 214). Indeed, many
 22 of those problems disproportionately impacted the Medical Monitoring Class because of the
 23

24
 25 ² *See* Settlement Agreement, Art. II, §2.1(q) (identifying proposed Class Counsel as Elizabeth J.
 26 Cabraser, Robert L. Lieff, and Steven E. Fineman of Lieff Cabraser Heimann & Bernstein;
 27 Samuel Issacharoff; James R. Dugan, II and TerriAnne Benedetto of the Dugan Law Firm,
 28 APLC, and William M. Audet of Audet & Partners, LLP); Art. II, §2.1(uuuuu) (identifying Mr.
 Audet as Subclass Counsel for the Personal Injury Class a/k/a “Subclass 1” and Ms. Benedetto as
 Subclass Counsel for the Medical Monitoring Class a/k/a “Subclass 2”).

1 inherent conflicts of interest of Settlement Counsel. As just one example, the proposed settlement
2 allowed for the settlement administrator to take funds from the relief provided to the Medical
3 Monitoring Class to pay claims to the Personal Injury Class. Silver Decl., §(V)(C) (citing ECF No.
4 11042-2, Ex. A to Cabraser Decl. (“Settlement Agreement”), §§ 7.4(b), 7.4(b)(i), 7.5)).

5 The interests of the Medical Monitoring Class were never adequately protected by subclass
6 counsel during the negotiation or settlement process. *Infra*, §§ II.C, IV.B.; *See generally* Silver
7 Decl. For example, no one—other than Fegan Scott LLC—had filed a complaint seeking to create
8 a separate class for future claimants until the settlement was proposed. Silver Decl., §5(A). That
9 was more than three-and-a-half years after the MDL leadership structure had been in place, and
10 more than a year after one of Settling Counsel filed a class action complaint on behalf of the
11 Personal Injury Class. *Id.*; *Ramirez v. Monsanto Company*, 3:19-cv-02224 (N.D. Cal.) (“*Ramirez*”)
12 (filed Apr. 24, 2019).³

13 Furthermore, Settling Counsel’s informal, private designation of provisional subclass
14 counsel failed to serve as an adequate substitute for truly independent representation. *Infra*, § IV.B.;
15 *See generally* Silver Decl. First, Settling Counsel purported to negotiate on behalf of current and
16 future claimants. *See* Silver Decl., §V(C); *supra*, n. 2 (the Settlement Agreement sought to appoint
17 the same two proposed Subclass Counsel attorneys as Settlement Class Counsel). The lawyer that
18 Settling Counsel assigned to represent the Medical Monitoring Class is an attorney at the Dugan
19 Law Firm, which filed at least one individual case on behalf of a Personal Injury Plaintiff who was
20 *already* diagnosed with NHL, Silver Decl., § V(B)(2), and has allegedly entered into one or more
21 inventory settlements with Defendants on behalf of numerous personal injury claimants,
22 Declaration of Elizabeth A. Fegan (“Fegan Decl.”), ¶11, attached as Ex. C. The Settlement also
23 purported to pay Subclass Counsel out of the entire class’s recovery, thus removing any incentive
24 Subclass Counsel could have to maximize the recovery of the Medical Monitoring Class over those
25

26 ³ The *Ramirez* complaint made no request for a medical monitoring subclass nor did it seek medical
27 monitoring relief until it was amended the same day that the proposed settlement was submitted
28 for Court approval. *See id.*; ECF No. 10039 (“*Ramirez Amended Complaint*”).

1 of the Personal Injury Plaintiffs. Silver Decl., §V(C).The actions of Settling Counsel and Settling
2 Subclass Counsel reflect a divided loyalty that cannot be fixed; no amount of “assurance” can fix
3 the very real concern about preferential treatment for current claimants or plaintiffs in inventory
4 settlements over the interests of the proposed class. Silver Decl., § V(B)(2).

5 Since the withdrawal of the Preliminary Approval Motion, negotiations have continued
6 between Monsanto and the very same counsel who have immutable conflicts of interest and *cannot*
7 *adequately represent the Medical Monitoring Class*. Fegan Decl., ¶ 9; *See* Silver Decl., § V(B)(2).
8 Movant’s counsel has conferred with Settling Counsel on multiple occasions but, to date, the only
9 counsel at the negotiating table for the Medical Monitoring Class are the very same ones with the
10 conflicts reflected in Professor Silver’s report. Fegan Decl., ¶¶ 4-11.

11 Without the formal appointment of independent counsel to represent the Medical
12 Monitoring Class, the class cannot, by definition, be ethically or adequately represented at the
13 negotiating table to ensure “an ample, inflation-protected fund for the future.” *Amchem Prods. v.*
14 *Windsor*, 521 U.S. 591, 626 (1997). The formal appointment of such counsel is required to provide
15 “structural assurance of fair and adequate representation for the diverse groups and individuals
16 affected.” *Id.* at 627. Accordingly, pursuant to the Supreme Court’s direction in *Amchem* and *Ortiz*
17 *v. Fibreboard Corp.*, 527 U.S. 815 (1999), and in light of the apparent conflict of interest revealed
18 by the Preliminary Approval Motion and terms of the settlement it sought to approve, Movants
19 respectfully request the Court grant this renewed motion for the appointment of Fegan Scott as
20 Interim Class Counsel for the Medical Monitoring Class.⁴

21 As reflected below, Fegan Scott exceeds the appointment criteria set forth in Fed. R. Civ.
22 P. 23(g). Together with their co-counsel, Fegan Scott has diligently investigated and pursued this
23 action, is committed to advancing the interests of the class, is comprised of highly experienced and
24 dedicated class action and complex litigation practitioners with an expertise in medical monitoring
25

26 ⁴ Hereinafter, Plaintiff’s counsel—Fegan Scott, RWP, Shindler, Anderson, Goplerud, & Weese,
27 P.C., and Cate, Terry & Gookins LLC—shall collectively be referred to as “Medical Monitoring
28 Counsel.”

1 actions, and has devoted the resources necessary to fully prosecute this action. To ensure that
 2 counsel can effectively negotiate, collaborate, and safeguard the Medical Monitoring Class's
 3 interests, this Court should appoint Fegan Scott as Interim Class Counsel for the Medical
 4 Monitoring Class.

5 **II. RELEVANT FACTUAL AND PROCEDURAL HISTORY**

6 **A. Summary of Factual Allegations against Defendants**

7 Since at least the 1970s, Defendants have manufactured and sold Roundup, an herbicide
 8 that contains the chemical glyphosate. American farmers have traditionally used Roundup to treat
 9 the vast majority of corn, soybean, and cotton acres planted in the United States. Commercial
 10 landscapers also widely employ Roundup when maintaining nurseries, parks, fields, and lawns.

11 Scientific evidence has established a clear association between glyphosate and genotoxicity,
 12 inflammation, and an increased risk of many cancers, including NHL. Despite knowledge,
 13 Defendants did not disclose those facts to consumers who purchased and have been exposed to the
 14 chemical, including farmers, farmworkers, and landscapers that regularly used substantial amounts
 15 of the product. Instead, Defendants actively concealed these truths from consumers.

16 **B. The Litigations**

17 *The Medical Monitoring Class Action.* Mr. Sheller brought his suit on behalf of himself
 18 and the Medical Monitoring Class: individuals who have been exposed to Roundup (and
 19 glyphosate) through their commercial and agricultural endeavors but have not yet developed
 20 cancer.⁵ Mr. Sheller is a farmer in Indiana who for years has routinely used Roundup on thousands
 21 of acres of his farmland. As a result of Defendants' conduct, Mr. Sheller and the Medical
 22 Monitoring Class members are subject to an increased risk of cancer, including lymphoma. His
 23 suit seeks to establish a medical monitoring program that monitors class members' health and
 24 ensures early diagnosis of Roundup-related cancers.

25
 26
 27 ⁵ The Medical Monitoring Class was named "Subclass 2" in the Preliminary Approval Motion;
 28 the Personal Injury Class—comprising those exposed to Roundup and already diagnosed with
 NHL—was referred to as "Subclass 1." Settlement Agreement, Art. I, §1.1; §1.2(a), (b).

1 Following significant pre-trial investigation and analysis, Mr. Sheller and his counsel filed
2 his suit on September 30, 2019 in the Southern District of Indiana. On November 12, 2019,
3 Plaintiff filed a Motion to Appoint Fegan Scott, LLC as Interim Class Counsel for the Medical
4 Monitoring Class and Riley Williams & Piatt as Interim Liaison Counsel. No. 1:19-cv-004063
5 (S.D. Ind.) (ECF No. 19) (“Motion to Appoint”). The Motion to Appoint was never ruled upon.
6 On November 18, 2019, Monsanto filed a Notice of Potential Tag-Along Action (MDL No. 2741,
7 ECF No. 1425), and the case was transferred to this MDL on December 4, 2019. (ECF No. 8137).

8 Plaintiff also filed a March 10, 2020 motion to appoint Fegan Scott LLC as interim lead
9 counsel for the Medical Monitoring Class in the MDL. ECF No. 9771. In that motion, Mr. Sheller
10 noted that settlement discussions between Defendants and counsel in the Personal Injury Cases
11 had been active and ongoing since at least spring 2019. However, pursuant to the Supreme Court’s
12 decision in *Amchem* and California Rule of Professional Conduct 1.7, separate counsel should have
13 been appointed for the two discrete groups present: i.e., the “currently injured” on the one hand
14 (here, the Personal Injury Cases), and the “exposure-only plaintiffs” on the other hand (here, the
15 Medical Monitoring Class). *Id.* at 626. The Supreme Court explained:

16 In significant respects, the interests of those within the single class
17 are not aligned. Most saliently, for the currently injured, the critical
18 goal is generous immediate payments. That goal tugs against the
19 interest of exposure-only plaintiffs in ensuring an ample, inflation-
20 protected fund for the future.

21 *Id.* See also Robinson Decl. and Silver Decl. Mr. Sheller’s motion was unopposed. See ECF No.
22 10289 (Apr. 7, 2020 Notice of Non-Opposition). In its April 27, 2020, order on that motion, the
23 Court recognized:

24 As Fegan Scott points out, the interests of people with exposure-
25 only claims may diverge from those who have been diagnosed with
26 cancer, because “for the current injured, the critical goal is generous
27 immediate payments,” which can conflict with “the interest of
28 exposure-only plaintiffs in ensuring an ample, inflation-protected
fund for the future.”

ECF No. 10587, p. 2 (quoting *Amchem Prods.*, 521 U.S. at 595). The Court nevertheless denied
Plaintiff’s motion without prejudice, stating that, at the time:

[T]he motion presents no reason to believe that negotiations between Monsanto and the currently sick will impact any future negotiations between Monsanto and the exposure-only medical-monitoring class. For example, the motion provided no evidence that these plaintiffs are competing over diminishing assets insufficient to discharge the potential liability. Nor does the motion advance any other interest that justifies departure from the standard order of operations for class actions.

Id. at 2. Unfortunately, however, these concerns have now become a reality.

The Personal Injury Cases. More than 18,000 individuals who contracted cancer because of Roundup have brought suit against Defendants in this MDL and in state court. In December 2016, this Court appointed a plaintiffs' counsel leadership structure for the Personal Injury Cases. (ECF No. 62). Since that time, general causation discovery has occurred, *Daubert* decisions have been rendered, and three Roundup personal injury cases have been tried, resulting in large verdicts. In April 2019, lead counsel for the Personal Injury Plaintiffs and Defendants were ordered to a confidential mediation. (ECF Nos. 3325, 4441). The Preliminary Approval Motion claims the "settlement discussions began in earnest" "in late July 2019." Cabraser Decl., ¶ 3. Those discussions are continuing now. Fegan Decl., ¶ 9.

C. The Withdrawn Settlement and Continuing Settlement Negotiations

1. The proposed settlement terms disproportionately prejudiced the Medical Monitoring Class.

On June 24, 2020, Settling Counsel filed a Motion for Preliminary Approval seeking to resolve the claims of both the Medical Monitoring Class and the Personal Injury Class and appoint themselves class and subclass counsel. But the settlement was plagued with problems, many of which were uniquely prejudicial to the Medical Monitoring Class. *See Silver Decl.* For example, the proposed settlement:

- delegated causation to a science panel, Settlement Agreement, §6.3;
- bound Medical Monitoring Class members to the determination of the science panel made during a four-year period, without the benefit of the scientific developments and data that may arise between the panel's determination and the member developing NHL (aside from an onerous, untenable procedure for re-opening the panel's process), *Id.*;

- 1 • defined subclasses but did not segregate the benefits between the subclasses (*e.g.*, it
- 2 allowed funds to be taken from the Medical Monitoring Class to make payments to
- 3 members of the Personal Injury Class), *e.g.*, *id.* at §7.4(b)(i);
- 4 • precluded Medical Monitoring Class members who are diagnosed after 2025 from applying
- 5 for the Interim Assistance Grant program (which comprised the bulk of the settlement
- 6 fund), *e.g.*, *id.* at §10.1(a)(i);
- 7 • included provisions allowing the settlement allocation to change after the science panel
- 8 reached its determination, without providing any safeguard to ensure the Medical
- 9 Monitoring Class would still be entitled to settlement funds or that the medical monitoring
- 10 program would continue, *e.g.*, *id.* §§7.4(b), 7.5; 30.1(c); and
- 11 • did not tie counsels' attorneys' fees to the subclasses they purported to represent, *id.*,
- 12 Article XXIV; Preliminary Approval Motion at 15, 31.

13 *See also* Silver Decl., § VI(C).

14 **2. The terms of the Settlement reflected immutable conflicts of interest**
 15 **which are important to understand the backdrop against which**
 16 **settlement negotiations continue.**

17 Settling Counsel failed to propose subclasses with separate representation until the
 18 settlement was proposed to the Court in June 2020. Silver Decl., §V(A). By that point, the
 19 leadership structure for the MDL had been in place for about three-and-a-half-years and Settling
 20 Counsel had been pursuing personal injury claims for over a year. *Id.*, §V(A). The Court had no
 21 opportunity to consider or address the adequacy of the proposed class, subclass representatives, or
 22 subclass counsel. *Id.*, §V(B). And the material shortcomings with Settling Counsel's belated
 23 proposals led to insurmountable flaws with both the settlement and the proposed leadership
 24 structure. *Supra*, § II.C.1., *Infra*, § IV.B.

25 For example, the very counsel charged with representing the Medical Monitoring Class has
 26 a conflict with that class. *See* Silver Decl., §V(B)(2). In the Preliminary Approval Motion, James
 27 R. Dugan and TeriAnne Benedetto of the Dugan Law Firm were named among Class Counsel. In
 28 addition to Ms. Benedetto's role representing the Settlement Class as a whole (including Personal

1 Injury Class members), she was to represent the conflicting interests of Subclass 2. Of further
2 concern, the Dugan Firm filed a personal injury case for a plaintiff *already* diagnosed with NHL.
3 *Ian M. Bodin v. Monsanto Company*, No: 2:19-cv-11362 (E.D.L.A. June 25, 2019), ECF No. 1, ¶
4 99. Moreover, the Dugan Firm has allegedly entered inventory settlements on behalf of numerous
5 other personal injury cases. Fegan Decl., ¶ 11.

6 The proposed settlement structure also failed to align the interests of subclass counsel and
7 subclass members by linking attorneys' fees to claimants' recoveries. Silver Decl., § IV(D). And
8 the settlement defined the class in such a way that *excluded* the proposed class representatives. *Id.*,
9 § V(B)(1). In other words, Settling Counsel reached and sought approval of a settlement on behalf
10 of people they did not represent. *Id.*, §V(B)(1).

11 Several interested parties filed motions to extend the deadline to respond that motion,
12 flagging some of the many problems with the proposed settlement. On July 6, 2020, the Court
13 entered an order in which it recognized several of these concerns. ECF No. 11182. Settling Counsel
14 subsequently withdrew their motion. ECF No. 11193.

15 **D. Meet and Confers**

16 On Friday, February 14, 2020, Mr. Sheller's counsel, Elizabeth Fegan and Jessica Meeder,
17 conferred with Lead Counsel Aimee Wagstaff, Robin Greenwald, and Michael Miller, and Liaison
18 Counsel Lori Andrus and Mark Burton via telephone regarding the basis for the renewed motion.
19 Lead Counsel advised that they opposed Mr. Sheller's March 2020 motion. Since the Motion for
20 Preliminary Approval was filed, Mr. Sheller's counsel, Elizabeth Fegan, conferred with Settling
21 Counsel on multiple occasions between June 26 and August 19, 2020 via telephone. They oppose
22 this motion. Fegan Decl., ¶¶ 4-11.

23 **III. LEGAL STANDARD**

24 Pursuant to Fed. R. Civ. P. 23(g)(3), this Court may "designate interim counsel to act on
25 behalf of a putative class before determining whether to certify the action as a class action." Interim
26 class counsel is responsible for all pre-certification activities including, *inter alia*, "making and
27 responding to motions, conducting... necessary discovery, moving for class certification, and
28

1 negotiating settlement.”⁶ A court should designate interim class counsel when it is “necessary to
2 protect the interests of the putative class.”⁷

3 In making its appointment, the Court must ensure that counsel will “fairly and adequately
4 represent the interests of the class”⁸ and must consider: (i) the work counsel has done in identifying
5 or investigating potential claims in the action; (ii) counsel’s experience in handling class actions,
6 other complex litigation, and the types of claims asserted in the action; (iii) counsel’s knowledge
7 of the applicable law; and (iv) the resources that counsel will commit to representing the class.⁹
8 The Court also “may consider any other matter pertinent to counsel’s ability to fairly and
9 adequately represent the interests of the class.”¹⁰ Counsel is not “adequate” pursuant to Rule 23 if
10 it has a conflict of interest.¹¹

11 **IV. ARGUMENT**

12 **A. Appointment of Interim Class Counsel is necessary to protect the 13 interests of the Medical Monitoring Class.**

14 This case poses a unique circumstance: it is part of a broad landscape of cases. But Mr.
15 Sheller’s case was the *only* one that sought to represent the Medical Monitoring Class to ensure
16 “an ample, inflation-protected fund for the future,” *Amchem Prods.*, 521 U.S. at 626, until Settling
17 Counsel amended the claims in the *Ramirez* complaint on the same day they filed their Preliminary
18 Approval Motion—i.e., *after* the settlement was reached. ECF No. 11039. But subclasses, with
19 independent counsel, should always have been in place when the Medical Monitoring Class’s
20 discrete rights were being litigated and negotiated. “The rationale is simple: how can the value of
21

22 ⁶ Manual for Complex Litigation (4th) at § 21.11.

23 ⁷ Fed. R. Civ. P. 23, 2003 Advisory Committee Notes.

24 ⁸ Fed. R. Civ. P. 23(g)(4).

25 ⁹ Fed. R. Civ. P. 23(g)(1)(A). *See also In re Navistar Maxxforce Engines Mktg., Sales Practices &*
26 *Prods. Liab. Litig.*, No. 2590, 2015 U.S. Dist. LEXIS 34662, at *9-10 (N.D. Ill. Mar. 5, 2015);
27 *Walker v. Discover Fin. Servs.*, No. 10-cv-6994, 2011 U.S. Dist. LEXIS 58803, at *8 (N.D. Ill.
28 May 26, 2011); *Simpkins v. Wells Fargo Bank, N.A.*, 2013 WL 12051028, at *1 (S.D. Ill. June 28,
2013) (observing that Rule 23(g)(1) factors are to be applied in appointing interim counsel).

¹⁰ Fed. R. Civ. P. 23(g)(1)(B).

¹¹ Fed. R. Civ. P. 23(a)(4); *see also Hanlon v. Chrysler Corp.*, 150 F.3d 1011, 1020 (9th Cir. 1998).

1 any subgroup of claims be properly assessed without independent counsel pressing its most
2 compelling case?” *Literary Works in Elec. Databases Copyright Litig. v. Thomson Corp.*, 654 F.3d
3 242, 253 (2d Cir. 2011) (referencing Ortiz).

4 In *Amchem*, class certification was sought to achieve a global settlement for both current
5 and future asbestos-related claims, both for claimants who were currently injured, and those who
6 may face future injuries. The Court noted the divergent interests of the class: those currently
7 injured have the goal of “generous immediate payments,” and the exposure-only plaintiffs seek
8 “an ample, inflation-protected fund for the future.” The Court noted the significance of these
9 differences, as the settlement included no adjustment for inflation, and only a few claimants per
10 year could opt out. The Court concluded there was “no structural assurance of fair and adequate
11 representation for the diverse groups.” *Id.* See also *Ortiz*, 527 U.S. at 815 (reaffirming “that a class
12 divided between holders of present and future claims ... requires division into homogeneous
13 subclasses under Rule 23(c)(4)(B), with separate representation to eliminate conflicting interests
14 of counsel.”); *Hanlon v. Chrysler Corp.*, 150 F.3d. 1011, 1020 (9th Cir. 1998) (“The Court found
15 that the clashing interests of present and future claimants presented
16 insurmountable conflicts for class counsel who could not possibly provide adequate
17 representation to both groups as required by Rule 23(a)(4).”).

18 While leadership for the Personal Injury Cases is well-positioned to advocate for their
19 clients in the ongoing settlement discussions, future claimants are entitled to separate
20 representation for prosecution and settlement negotiations. In fact, pursuant to *Amchem* and
21 California Rule of Professional Conduct 1.7, such independent representation is required. As ethics
22 expert Mary Robinson, Esq. originally opined, lead counsel’s responsibilities to the Personal Injury
23 Plaintiffs create a “significant risk of materially limiting their representation of the Medical
24 Monitoring Class” because the two groups of plaintiffs have “differing and competing goals.”
25 Robinson Decl. at 5. When the Motion For Preliminary Approval was filed, Medical Monitoring
26 Counsel also obtained the expert opinion of Professor Charles Silver. See Ex. A. Professor Silver
27 opined that the settlement lacked required structural protections to ensure that future claimants are
28

1 represented adequately, including subclasses with subclass representatives treated as fiduciaries,
2 and court-appointed subclass counsel whose fees are tied to the subclass's recovery. *Id.*, §IV.

3 Indeed, subclasses are required to ensure the named parties will fairly and adequately
4 protect the interests of the class in accordance with Rule 23(a)(4). Silver Decl., § IV(A) (citing
5 *Amchem* (“Most saliently, for the currently injured, the critical goal is generous immediate
6 payments. That goal tugs against the interest of exposure-only plaintiffs in ensuring an ample,
7 inflation-protected fund for the future.”)). The implementation of subclasses is a “structural”
8 measure intended to ensure adequate representations of person with distinctive interests. *Id.* (citing
9 *In re Joint Eastern and Southern Dist. Asbestos Litigation*, 982 F.2d 721, 742-743 (1992), *modified*
10 *on reh'g sub nom. In re Findley*, 993 F.2d 7 (1993) (“the adversity among subgroups requires that
11 the members of each subgroup cannot be bound to a settlement except by consents given by those
12 who understand that their role is to represent solely the members of their respective subgroups.”).
13 As Professor Silver noted, *id.*, in *Ortiz*, the Supreme Court reinforced *Amchem*'s message: “[I]t is
14 obvious after *Amchem* that a class divided between holders of present and future claims . . . requires
15 division into homogeneous subclasses under Rule 23(c)(4)(B), with separate representation to
16 eliminate conflicting interests of counsel.” *Ortiz*, 527 U.S. at 856. Separate counsel was and
17 remains necessary to protect the interests of the Medical Monitoring Class and ensure “an ample,
18 inflation-protected fund for the future,” *Amchem Prods.*, 521 U.S. at 626.

19 **B. Settling Counsel's belated, informal designation of subclass**
20 **counsel fails to protect the class's interests.**

21 The informal leadership structure under which Settling Counsel continues to proceed does
22 not meet the requirements of *Amchem*, *Ortiz*, or Rule 23. See Silver Decl., § V. “Rule 23 demands”
23 that “structural assurance” be in place “prior to the settlement itself.” *Smith v. Sprint Commc'ns*
24 *Co., L.P.*, 387 F.3d 612, 614 (7th Cir. 2004) (citing *Amchem Prods.*, 521 U.S. at 627). Indeed, the
25 settlement in *Ortiz* was overturned because “the District Court took no steps *at the outset* to ensure
26 that the potentially conflicting interests of easily identifiable categories of claimants [were]
27 protected by provisional certification of subclasses under Rule 23(c)(4).” 527 U.S. at 831-32
28 (emphasis added); see also Silver Decl., § V.A.

1 While the Motion for Preliminary Approval claimed that the subclasses were represented
2 “by their own proposed Subclass counsel” “during the critical stages of the negotiations,”
3 Preliminary Approval Motion at 16, there is neither support for subclass counsel’s independence
4 nor an explanation of what Settling Counsel believes to be “the critical stages of the negotiations.”
5 Silver Decl., §V(B)(2). *See also* Declaration of Elizabeth J. Cabraser in support of the Preliminary
6 Approval Motion (“Cabraser Decl.”), ECF No. 11942-1, ¶ 6 (claiming the subclasses were
7 represented “during the necessary stages of the negotiations”).

8 Indeed, the proposed leadership structure failed to police potential conflicts among counsel.
9 Silver Decl., § V(B)(2). Both lawyers named to represent the subclasses in the MDL are associated
10 with law firms that represent clients asserting personal injury claims (i.e., current claimants with
11 interests opposing those of the future claimants that make up the Medical Monitoring Class). *Id.*
12 The interests of The Dugan Firm’s personal injury plaintiffs are plainly antagonistic to the Medical
13 Monitoring Class Ms. Benedetto sought to represent. *Amchem*, 521 U.S. at 626 (noting the
14 competing goals of “generous immediate payments” and “an ample, inflation-protected fund for
15 the future.”). *See also* Silver Decl., §V(B)(2) (citing *Ortiz*, 527 U.S. at 855, in which the Supreme
16 Court noted that the plaintiffs’ attorneys settled their signed clients’ cases outside the class action
17 and was bothered by the fact that the plaintiffs in “the settled inventory claims . . . appeared to
18 have obtained better terms than the class members.”).

19 Ms. Benedetto also purports to represent the interests of the Medical Monitoring Class
20 while acting as counsel for the Settlement Class as a whole. *See Ortiz*, 527 U.S. at 856 (“an attorney
21 who represents another class against the same defendant may not serve as class counsel”) (citing
22 Moore’s Federal Practice § 23.25[5][e], p. 23-149 (3d ed. 1998)); *Literary Works*, 654 F.3d at 266
23 (invalidating settlement and requiring subclasses even though “the attorneys conducting the
24 negotiations” represented the class as a whole “from the outset” and “[n]o claims unique to a
25 portion of the class [were] forfeited without compensation.” *id.* at 261-62 (Straub J., dissenting)).

26 In addition, the Preliminary Approval Motion fails to tie attorneys’ fees to the recovery of
27 the class that counsel purports to represent. Silver Decl., §V(C). The motion states that proposed
28

1 Class Counsel will seek up to \$150 million for fees and expenses but says nothing about how class
2 and subclass counsel will be compensated. Silver Decl., §V(C). In fact, proposed Subclass Counsel
3 are *also* named as proposed Class Counsel. *Supra*, n. 2; Silver Decl., §V(C) (If subclass counsel
4 are being paid out of the entire class’s recovery, then “the lawyers had no financial reasons to care
5 about how their respective subclasses fared”).

6 Settling Counsel cannot now seek appointment as interim counsel of the Medical
7 Monitoring Class to alleviate these conflicts. Belated, subjective assessments of settlement
8 allocation by conflicted fiduciaries are tainted and untrustworthy, particularly if—as implicitly
9 revealed in the terms of the settlement agreement here—subclass counsel’s financial ties run to the
10 class as a whole rather than only the subclasses they seek to represent. Silver Decl., §§IV(B)-(C),
11 VI. Mr. Sheller’s concerns are not merely hypothetical—“[i]mportant parts of the proposed
12 settlement reflect the lawyers’ indifference to” the Medical Monitoring Class, whose claims and
13 relief were jeopardized in the proposed Settlement Agreement. Silver Decl., §V(I)(C); *Supra*, §
14 II.C. Given these conflicts of interest, which cannot be resolved by waiver, the Medical Monitoring
15 Class must be provided with independent counsel who are empowered to investigate and advance
16 the interests of the class members.

17 **C. Fegan Scott should be appointed interim class counsel.**

18 Rule 23(g)(1)(A)(i) directs the court to consider “the work counsel has done in identifying
19 or investigating potential claims in the action.” Fegan Scott, together with RWP, Shindler,
20 Anderson, Goplerud, & Weese, P.C. and Cate, Terry & Gookins LLC, are the reason that the
21 Medical Monitoring Class has an avenue for recovery. *See* Fegan Decl., Exs. 1-4 (firm resumes).

22 Thousands of plaintiffs and their counsel are pursuing personal injury cases against the
23 Defendants on the theory that Roundup caused their cancer and other serious diseases. But not one
24 of these actions sought to protect the thousands of consumers who were exposed to significant
25 quantities of Roundup and have an increased risk of developing these diseases. While Settling
26 Counsel filed an 11th-hour amendment in *Ramirez* to include medical monitoring, that is a far cry
27 from the unconflicted representation to which the Medical Monitoring Class is entitled.
28

1 Medical Monitoring Counsel comprise the only team that identified this significant yet
2 unmet need. Medical Monitoring Counsel diligently investigated the underlying factual and legal
3 theories, narrowly tailored this case and the current class definition pursuant to those efforts, and
4 drafted a thoughtful, comprehensive complaint. Counsel have also consulted with experts to ensure
5 they seek the best diagnostic program for the Medical Monitoring Class.

6 Fegan Scott also meets and exceed the Rule 23(g)(1)(A)(ii) and (iii) requirements, which
7 evaluate counsel's experience as well as the knowledge of the applicable law raised in an action.
8 Founded in 2019 but built upon more than five decades of collective class action experience, Fegan
9 Scott is a nationwide class-action firm dedicated to helping victims of negligence, fraud, abuse,
10 and discrimination. Its founding partner and Managing Member, Beth Fegan has more than two
11 decades of experience in complex class action litigation, including medical monitoring class
12 actions. A sampling of Ms. Fegan's medical monitoring cases appears on the firm resume. Fegan
13 Decl., Ex. 1. Fegan Scott attorneys Timothy Scott, Melissa Clark, and Jessica Meeder also stand
14 ready, willing, and able to assist in the prosecution of this action as appropriate. *Id.* Riley Williams,
15 Shindler Anderson, and Cate Terry also have a depth and breadth of class action and complex
16 litigation experience. *See* Fegan Decl., Exs. 2-4.

17 Finally, Rule 23(g)(1)(A)(iv) considers the resources that counsel will commit to
18 representing the class. As experienced class action attorneys, Fegan Scott, RWP, and Shindler
19 Anderson fully understand the substantial investment of time and resources necessary to properly
20 pursue and lead these types of litigations and they are committed to dedicating those resources to
21 the best interests of the class.

22 **V. CONCLUSION**

23 To adequately protect the Medical Monitoring Class's interests, Movants request that this
24 Court appoint Elizabeth A. Fegan of Fegan Scott LLC as interim class counsel for the Medical
25 Monitoring Class, including for the purpose of settlement negotiations.

26 Dated: August 24, 2020

27 Respectfully submitted,
28 /s/ Elizabeth A. Fegan
Elizabeth A. Fegan

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

FEGAN SCOTT LLC
150 S. Wacker Dr., 24th Floor
Chicago, IL 60606
T: 312-741-1019
F: 312-264-0100
beth@feganscott.com

Jessica H. Meeder
FEGAN SCOTT LLC
1200 G Street, N.W., Ste. 800
Washington, D.C. 20005
T: 202-434-8992
F: 202-217-2814
jessica@feganscott.com

Melissa Ryan Clark
FEGAN SCOTT LLC
140 Broadway, 46th Floor
New York, NY 10005
T: 347-353-1150
F: 312-265-0100
melissa@feganscott.com

William Riley
Anne Medlin Lowe
RILEY WILLIAMS & PIATT, LLC
301 Massachusetts Ave.
Indianapolis, IN 46204
T: 317-633-5270
F: 317-426-3348
wriley@rwp-law.com
alowe@rwp-law.com

J. Barton Goplerud
SHINDLER, ANDERSON,
GOPLERUD & WEESE, P.C.
5015 Grand Ridge Drive, Suite 100
West Des Moines, IA 50265
T: 515-223-4567
F: 515-223-8887
goplerud@sagwlaw.com

Russell Cate
CATE, TERRY & GOOKINS LLC
301 East Carmel Drive, Suite C300
Carmel, IN 46032
T: 317-564-0016
F: 317-564-0599
rcate@ctglaw.com

*Counsel for Plaintiff and Proposed Interim
Lead Counsel for the Medical Monitoring
Class*

CERTIFICATE OF SERVICE

I certify that, on August 24, 2020, a copy of the foregoing Plaintiff's Renewed Motion to Appoint Fegan Scott, LLC as Interim Class Counsel for the Medical Monitoring Class was served on all counsel of record via ECF.

Dated: August 24, 2020

/s/ Elizabeth A. Fegan
Elizabeth A. Fegan
FEGAN SCOTT LLC
150 S. Wacker Dr., 24th Floor
Chicago, IL 60606
T: 312-741-1019
F: 312.264.0100
beth@feganscott.com

*Counsel for Plaintiff and
Proposed Interim Lead
Counsel for the Medical
Monitoring Class*